Unresectable stage III non-small-cell lung cancer: Have we made any progress?

Table 1 Survival data from randomized trials comparing induction chemotherapy followed by concurrent chemoradiation therapy with concurrent chemoradiation therapy alone of chemotherapy followed by radiation therapy alone in non-small-cell lung cancer

Trial	Patients (n)	Schedule	Median survival(mo)	Survival (%)
Vokes et al[11]	366	CP × 2 → weekly CP + 66 Gy	23	31 (3 yr)
		Weekly CP + 66 Gy	19	29
Huber et al[16]	214	CP × 2 → weekly P + 60 Gy	18.7	33 (3 yr)
		CP × 2 → 60 Gy	14.1	14 (3 yr)
Gervais et al[14]	584	PVi × 2 → daily C + 66 Gy	14	-
		PVi × 2 → 66 Gy	11	-
Clamon et al[13]	283	PVb × 2 → weekly C + 60 Gy	13.4	13 (4 yr)
		PVb × 2 → 60 Gy	13.5	10
Scagliotti et al[15]	89	DC × 2 → D + 60 Gy	14.9	55.8 (1 yr)
		DC × 2 → 60 Gy	14	58.7

CP: Carboplatin/paclitaxel; P: Paclitaxel; PVi: Cisplatin/vinorelbine; PVb: Cisplatin/vinblastin; DC: Docetaxel/cisplatin; D: Docetaxel.

Table 2 Survival data from phase II and III trials using concurrent chemoradiation therapy followed by consolidation chemotherapy in non-small-cell lung cancer

Trial	Patients (n)	Schedule	Median survival(mo)	Survival (%)
Belani et al[10]	92	Weekly CP + 63 Gy → CP × 2	16.3	17 (3 yr)
Albain et al[96]	50	PE × 2 + 61 Gy → PE × 2	15	15 (5 yr)
Gandara et al[43]	83	PE × 2 + 61 Gy → D × 3	26	29 (5 yr)
Lau et al[97]	34	Weekly C + biweekly P + 61 Gy → CP × 2	17	40 (2 yr)
Hanna et al[44]	73	PE × 2 + 59.4 Gy → D × 3	21.2	27.1 (3 yr)

CP: Carboplatin/paclitaxel; P: Paclitaxel; PE: Cisplatin/etoposide; D: Docetaxel.